Saad Alqahtani

Mr. Saad Alqahtani

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 May 2010 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AAAbdulaziz M. Al-Swailem
Abdulaziz M. Al-Swailem
MSMaher M. Shehata
Maher M. Shehata
FAFaisel M. Abu-Duhier
Faisel M. Abu-Duhier
EAEssam J. Al-Yamani
Essam J. Al-Yamani
KAKhalid A. Al-Busadah
Khalid A. Al-Busadah
Hasan OtuHasan Otu
Hasan Otu
Despite its economical, cultural, and biological importance, there has not been a large scale sequencing project to date for Camelus dromedarius. With the goal of sequencing complete DNA of the organism, we first established and sequenced camel EST libraries, generating 70,272 reads. Following trimming, chimera check, repeat masking, cluster and assembly, we obtained 23,602 putative gene sequences, out of which over 4,500 potentially novel or fast evolving gene sequences do not carry any homology to other available genomes. Functional annotation of sequences with similarities in nucleotide and protein databases has been obtained using Gene Ontology classification. Comparison to available full length cDNA sequences and Open Reading Frame (ORF) analysis of camel sequences that exhibit homology to known genes show more than 80% of the contigs with an ORF>300 bp and ∼40% hits extending to the start codons of full length cDNAs suggesting successful characterization of camel genes. Similarity analyses are done separately for different organisms including human, mouse, bovine, and rat. Accompanying web portal, CAGBASE (http://camel.kacst.edu.sa/), hosts a relational database containing annotated EST sequences and analysis tools with possibility to add sequences from public domain. We anticipate our results to provide a home base for genomic studies of camel and other comparative studies enabling a starting point for whole genome sequencing of the organism.

10 January 2022 in Expert Systems with Applications
Verified
Journal Article
Open access
AAAbdullah Almuhaimeed
Abdullah Almuhaimeed
MAMohammed A. Alhomidi
Mohammed A. Alhomidi
EAEmad Alamoud
Emad Alamoud
SASaad Alqahtani
Saad Alqahtani

2 May 2026 in Biology
Verified
Journal Article
Open access
PDF file
MAMohammed M. H. Albariqi
Mohammed M. H. Albariqi
IAIbrahim Alradwan
Ibrahim Alradwan
SASaad Alqahtani
Saad Alqahtani
MMMajed A. Majrashi
Majed A. Majrashi
BABasem Almutiri
Basem Almutiri
SASultan Alzahrani
Sultan Alzahrani
Diabetic peripheral neuropathy (DPN) is a common and debilitating complication of diabetes mellitus which affects individuals with both type 1 and type 2 diabetes mellitus (T2DM), presenting with sensory loss, pain, and progressive nerve dysfunction. DPN pathogenesis is multifactorial: chronic hyperglycemia activates the polyol, hexosamine, and protein kinase C (PKC) pathways, increases advanced glycation end-products, and drives oxidative stress, mitochondrial dysfunction, inflammation, and impaired neurotrophic signaling. In addition to hyperglycemia-driven mechanisms, dyslipidemia and microvascular insufficiency exacerbate neural ischemia and metabolic stress. Recent mechanistic, animal, and associative human studies further implicate amyloidogenic toxicity, particularly from human islet amyloid polypeptide (hIAPP), as a plausible contributory factor in peripheral nerve degeneration in T2DM, linking protein misfolding and aggregation to axonal damage and demyelination in DPN. Despite increased understanding of these mechanisms, current treatments remain mainly symptomatic. Emerging therapeutic strategies, including antioxidants, anti-inflammatory agents, modulators of mitochondrial function, amyloid oligomer modulators, neurotrophic enhancers, and regenerative approaches such as stem cells and gene-based therapies, offer potential to modify disease progression. The strength of evidence across these methods varies, ranging from mechanistic and animal studies to early human research and, in some cases, randomized clinical trials. Therefore, although several candidates show potential to alter the disease, few have demonstrated consistent benefits on objective measures of nerve structure or function in large clinical trials. This review summarizes the key mechanisms driving DPN in T2DM and highlights promising therapeutic innovations poised for clinical translation.

19 August 2024 in SSRN Electronic Journal
Verified
Preprint
Open access
AAAbdullah Almuhaimeed
Abdullah Almuhaimeed
FAFawaz Khaled Alarfaj
Fawaz Khaled Alarfaj
MAMohammed Alreshoodi
Mohammed Alreshoodi
MGMansoor A. Al Ghamdi
Mansoor A. Al Ghamdi
SASaad Alqahtani
Saad Alqahtani
SAShahad Abdulaziz Alomayrah
Shahad Abdulaziz Alomayrah

26 May 2026 in Frontiers in Genome Editing
Verified
Journal Article
Open access
PDF file
AAAisha Yousef Alhumoudi
Aisha Yousef Alhumoudi
AAAminah Ghazi Alotaibi
Aminah Ghazi Alotaibi
NANada Fahad Alosaimi
Nada Fahad Alosaimi
AAAbdulrahman Alshalani
Abdulrahman Alshalani
SASaad Alqahtani
Saad Alqahtani
MAMohammed M. H. Albariqi
Mohammed M. H. Albariqi
Advancements in genome editing have established a new frontier for the treatment of various genetic diseases, including sickle cell disease (SCD). SCD, the most prevalent monogenic blood disorder, causes severe pain, organ damage, and reduced life expectancy. The recent clinical approval of clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9-based gene therapies for severe sickle cell anemia marks a significant milestone in treating genetic diseases. Despite these breakthroughs, limitations in CRISPR technology persist, requiring further innovation. Alternative approaches, such as the Fanzor (Fz) system, are being developed to complement CRISPR’s capabilities. Unlike CRISPR, which is typically encoded within prokaryotic organisms, Fz is encoded in the eukaryotic genome, offering a universal RNA-guided mechanism applicable across all life kingdoms. Fz’s eukaryotic origin may facilitate more efficient delivery across diverse cell types and tissues, enhancing its therapeutic potential. Here, we will review the current successes and limitations of the CRISPR technology in editing mutation associated with SCD. Additionally, we will explore the potential role of Fz as a genome-editing tool for SCD, a field where its application has not yet been studied.